PCSK9 in the Immunometabolism of Type 2 Diabetes
- 1Diabetology Outpatient Service, Azienda Socio-Sanitaria Territoriale del Garda, 25024 Leno, Italy
- 2Diabetology Outpatient Service, Azienda Socio-Sanitaria Territoriale della Franciacorta, 25032 Chiari, Italy
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition reduces cardiovascular events in type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates an original corpus of 108 appraised publications, with targeted additions during revision. It evaluates whether findings from different compartments and experimental perturbations can be transferred to particular treatments and clinical outcomes. Mechanistic evidence implicates receptor trafficking, intracellular cholesterol, mitochondrial stress and inflammatory signalling. Effects vary by cell type and compartment: local PCSK9 promotes injury in some models but preserves pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing are therefore distinct exposures. Human biomarker and imaging studies provide translational signals but generally cannot isolate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile, without demonstrating clinically meaningful glucose lowering. PCSK9 has broader immunometabolic functions, but the available evidence does not quantify an additional clinical benefit independent of atherogenic lipoprotein lowering. Tissue-specific mechanisms and causal mediation require further investigation.
Related
- Roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the regulation of hepatic triglyceride metabolism
- Association Between Glycemic Variability and Bone Turnover and the Sema3A Signaling Pathway in Postmenopausal Women with Type 2 Diabetes Mellitus
- Plasma Lipids Associated with Endothelial Dysfunction in Patients with Type 2 Diabetes: A Cross-Sectional Study Using Lipidomic Analysis
- Role of Uridine Phosphorylase 1 (UPP1) in Pancreatic β-Cell Physiology and Its Dysregulation in Obesity and Type 2 Diabetes
- RNA m6A Modification in Immunometabolism: Context-Dependent Mechanisms and Therapeutic Perspectives
BibTeX
@article{villari2026pcsk9,
title = {{PCSK9 in the Immunometabolism of Type 2 Diabetes}},
author = {Provvidenza Villari and Antonio Maria Labate},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219723},
url = {https://www.mdpi.com/1422-0067/27/21/9723},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - PCSK9 in the Immunometabolism of Type 2 Diabetes
AU - Provvidenza Villari
AU - Antonio Maria Labate
PY - 2026
DA - 2026/10/29
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219723
UR - https://www.mdpi.com/1422-0067/27/21/9723
AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition reduces cardiovascular events in type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates an original corpus of 108 appraised publications, with targeted additions during revision. It evaluates whether findings from different compartments and experimental perturbations can be transferred to particular treatments and clinical outcomes. Mechanistic evidence implicates receptor trafficking, intracellular cholesterol, mitochondrial stress and inflammatory signalling. Effects vary by cell type and compartment: local PCSK9 promotes injury in some models but preserves pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing are therefore distinct exposures. Human biomarker and imaging studies provide translational signals but generally cannot isolate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile, without demonstrating clinically meaningful glucose lowering. PCSK9 has broader immunometabolic functions, but the available evidence does not quantify an additional clinical benefit independent of atherogenic lipoprotein lowering. Tissue-specific mechanisms and causal mediation require further investigation.
SN - 1422-0067
ER -